Results of polidocanol endovenous microfoam in clinical practice

Kim, Pamela S.; Elias, Steven M.; Gasparis, Antonios P.; Labropoulos, Nicos

doi:10.1016/j.jvsv.2020.04.015

Cited by 10 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of truncal vein treatments involve foam polidocanol with a concentration ranging from 1% to 3%. The hyperpigmentation rates reported by all RCTs and non‐RCTs during this analysis (liquid and foam) were 7%–45.8% for polidocanol 1%, 21–26 16%–17% for polidocanol 2% 27,28 and 7.4%–32.5% for polidocanol 3% 21,22,24,25,28–30 …”

Section: Resultsmentioning

confidence: 72%

“…Most sclerotherapies with 0.5%–3% polidocanol were performed using the Tessari method for foam production (10 studies). One study used Turbofoam for foam generation, 22 and another used polidocanol endovenous microfoam 1% 26 . Regarding the type of gas used for foam production, one study compared air‐based foam and CO 2 ‐based foam and reported significantly less hyperpigmentation in the CO 2 group ( p ‐value < 0.0001).…”

Section: Resultsmentioning

confidence: 99%

“…One study used Turbofoam for foam generation, 22 and another used polidocanol endovenous microfoam 1%. 26 Regarding the type of gas used for foam production, one study compared air-based foam and CO 2 -based foam and reported significantly less hyperpigmentation in the CO 2 group (p-value < 0.0001). Detailed data regarding pigmentation according to the polidocanol concentrations used were not collected.…”

Section: Telangiectasia and Reticular Varicose Veinsmentioning

confidence: 99%

See 2 more Smart Citations

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Bossart

Daneluzzi

Cazzaniga

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Skin hyperpigmentation after sclerotherapy with polidocanol‐containing sclerosants is a common local side effect. Sclerotherapists should be familiar with factors that trigger hyperpigmentation after sclerotherapy with polidocanol‐containing sclerosants. A systematic literature review of works reporting hyperpigmentation after sclerotherapy for telangiectasias, reticular veins, side branches and truncal varices with polidocanol‐containing sclerosants was performed. Reported incidence rates, follow‐up periods and potentially triggering factors were assessed and analysed. The search yielded 1687 results; of these, 27 reports met the inclusion criteria. The incidence of hyperpigmentation seemed to increase with higher concentrations of polidocanol and was more evident after sclerotherapy for epifascial veins than for intrafascial truncal veins when the polidocanol concentration was more than 0.25%. Regarding sclerotherapy for telangiectasias and reticular veins, the incidence of hyperpigmentation ranged between 2% and 25% for polidocanol 0.25% (liquid and foam), between 12.5% and 67.9% for polidocanol 0.5% (liquid and foam) and between 13% and 73% for polidocanol 1% (liquid and foam). Regarding truncal veins, the incidence ranged from 7% to 45.8% for polidocanol 1% (liquid and foam), from 16% to 17% for polidocanol 2% (foam) and from 7.4% to 32.5% for polidocanol 3% (liquid and foam). Regarding the treatment of side branches, the incidence of hyperpigmentation ranged from 5.6% to 53% for both foam and liquid sclerotherapy. Regarding the duration of hyperpigmentation, there are few data describing reticular veins and telangiectasias. Hyperpigmentation persisting for more than 6 months has been reported to have an incidence of up to 7.5%. Hyperpigmentation persisting for more than 1 year after foam polidocanol 1%–3% treatment for truncal veins has an incidence ranging from 8.1% to 17.5%. Other factors such as higher volumes and compression therapy after treatment seem to have a minor influence. Data regarding hyperpigmentation after polidocanol‐related sclerotherapy are poor and should be improved by higher‐quality research.

show abstract

Section: Resultsmentioning

confidence: 72%

Section: Resultsmentioning

confidence: 99%

Section: Telangiectasia and Reticular Varicose Veinsmentioning

confidence: 99%

See 1 more Smart Citation

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Bossart

Daneluzzi

Cazzaniga

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The full-text reading and application of the inclusion and exclusion criteria resulted in the inclusion of 16 studies in the present systematic review. We excluded 65 studies for the following reasons (Appendix 2): reviews with overlapping data, 7,8 primary outcome not reported, [9][10][11][12][13][14][15][16][17][18] not written in English, [19][20][21][22][23][24][25][26][27][28][29][30][31] conference abstracts, overlapping data with an already included report by same author, 56 data not yet available, 57 full text not available, 58 no distinction between primary and secondary AASV incompetence, 59 no distinction in outcome between GSVand AASV, 60-62 and other outcome. [63][64][65][66][67][68][69][70][71] A flow chart of the selection procedure is shown in Figure 1.…”

Section: Study Selectionmentioning

confidence: 99%

A systematic review and meta-analysis of treatment modalities for anterior accessory saphenous vein insufficiency

et al. 2021

View full text Add to dashboard Cite

Objective To investigate and compare the outcomes of the available treatment modalities for anterior accessory saphenous vein (AASV) incompetence. Methods A systematic literature search was performed in MEDLINE, Embase, and the Cochrane Library. Studies reporting the outcomes of patients who were treated for primary AASV incompetence were included. The methodologic quality of the articles was assessed using the Methodological Index for Non-Randomized Studies (MINORS). A random-effects model was used to estimate anatomic success, defined as AASV occlusion. The secondary outcomes were pain during and after treatment, venous clinical severity score, quality of life, esthetic result, time to return to daily activities, and complications. Results The search identified 860 articles, of which 16 met the inclusion criteria. A total of 609 AASVs were reported. The included studies were of poor or moderate quality according to MINORS score. The pooled anatomic success rates were 91.8% after endovenous laser ablation and radiofrequency ablation (EVLA, RFA, 11 studies), 93.6% after cyanoacrylate closure (3 studies), and 79.8% after sclerotherapy (2 studies). The non-pooled anatomic success rate was 97.9% after phlebectomy and 82% after CHIVA. Paresthesia was seen after EVLA in 0.7% of patients (6 studies). Phlebitis was seen in 2.6% of patients after RFA (2 studies), 27% after sclerotherapy (1 study), and 12% after the phlebectomy (1 study). Deep venous thrombosis and skin burn did not occur. Conclusion Treatment of AASV incompetence is safe and effective. Despite limited evidence, occlusion of the AASV can be achieved with endovenous thermal ablation and cyanoacrylate. There does not appear to be a benefit of EVLA compared to RFA regarding treatment efficacy. Phlebectomy shows promising results if the saphenofemoral junction is competent. Lower results are seen after sclerotherapy and CHIVA. However, studies with sufficient sample sizes of solely treatment of AASV incompetence are needed to draw firm conclusions.

show abstract

Polidocanol

2021

Reactions Weekly

View full text Add to dashboard Cite

Results of polidocanol endovenous microfoam in clinical practice

Cited by 10 publications

References 29 publications

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review

A systematic review and meta-analysis of treatment modalities for anterior accessory saphenous vein insufficiency

Polidocanol

Contact Info

Product

Resources

About